[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urge-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urge-incontinence":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,76,104,146,170,199,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100629333","phase-4-low-intensity-shockwave-therapy-versus-solifenacin-for-the-treatment-of-overactive-bladder-in-women-100629333",false,"NCT07473310","Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women","Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* OAB symptoms persisting for ≥3 months.\n* OAB Symptom Score (OABSS) ≥7.\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\n* Active urinary tract infection.\n* Stress urinary incontinence as primary diagnosis.\n* Pelvic organ prolapse stage ≥II.\n* History of pelvic radiation or surgery within 6 months.\n* Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout.\n* Pregnancy or breast feeding.\n* Neuropathic diseases or psychological disorders.\n* History of urogenital malignancy.\n* Uncontrolled DM (HbA1c \\> 6.8)\n* Uncorrected coagulopathy or severe cardiovascular disease.\n* Contraindication to solifenacin e.g.: closed angle glaucoma)","FEMALE","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women.\n\nThe main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy.\n\nResearchers will compare Li-SWT with oral solifenacin succinate, a commonly used antimuscarinic medication for OAB.\n\nParticipants will be randomly assigned to receive either Li-SWT once weekly for 8 weeks or solifenacin 5 mg taken orally once daily for 12 months. All participants will complete symptom questionnaires and three-day voiding diaries and will undergo uroflowmetry, post-void residual measurement, and filling cystometry at specified time points during follow-up.",[26,27],"Overactive Bladder (OAB)","Urge Incontinence",[29,30,31,32],"OAB","overactive bladder","low intensity shockwave","solifenacin","RECRUITING","2026-03-10",{"date":36,"type":37},"2026-03-16","ACTUAL",{"date":39,"type":37},"2025-11-11",{"date":41,"type":20},"2027-12",{"name":43,"class":44},"Mansoura University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100402988","fluoroscopy-radiation-reduction-during-sacral-neuromodulation-lead-placement-100402988","NCT04527445","Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement","Reduction in Fluoroscopy Radiation Exposure During Lead Implantation for Sacral Neuromodulation: A Randomized Prospective Study","Inclusion Criteria:\n\n* Patients undergoing lead implantation for sacral neuromodulation that have overactive bladder as defined by urinary urgency, frequency, nocturia with or without urgency incontinence.\n\nExclusion Criteria:\n\n* neurogenic bladder, BMI \\>40, or peripheral neuropathy.","ALL","89 Years",{"count":56,"type":20},44,[58],"NA","Fluoroscopy is performed when placing a lead during a sacral neuromodulation procedure. During lead placement, subjects will receive either conventional or experimental fluoroscopic settings. The radiation exposure will be compared between the two groups.",[61,62,27,63],"Radiation Exposure","Overactive Bladder","Urgency-frequency Syndrome",[65,66],"Sacral Neuromodulation","Fluoroscopy","2026-03-04",{"date":69,"type":37},"2026-03-06",{"date":71,"type":20},"2026-06",{"date":73,"type":20},"2027-06",{"name":75,"class":44},"Loma Linda University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100533469","percutaneous-nerve-evaluation-trial-time-100533469","NCT06226220","Percutaneous Nerve Evaluation Trial Time","Trial Time for Percutaneous Nerve Evaluation in Patients Undergoing Sacral Neuromodulation for Urgency Urinary Incontinence or Urgency-frequency: a Randomized Control Trial","Inclusion Criteria:\n\n* Non-pregnant women \\>\u002F=18 years old undergoing sacral neuromodulation (SNM) treatment for urgency urinary incontinence (UUI) or urgency-frequency (UF) who have elected to undergo testing phase with a PNE\n* \\>\u002F=5 UUI episodes on a 3-day bladder diary with urge incontinence representing \\>\u002F=50% of total incontinence episodes recorded or \\>\u002F=8 per day for 2 days on a 3-day bladder diary\n* Willing and able to complete all study related items and interviews\n* Grossly neurologically normal exam\n\nExclusion Criteria:\n\n* SNM indication of non-obstructive urinary retention or isolated fecal incontinence\n* Severe or poorly controlled diabetes (defined as HgbA1c \\>\u002F=8.0) or diabetes with peripheral nerve involvement\n* Neurological diseases such as multiple sclerosis, clinically significant peripheral neuropathy, or complete spinal cord injury\n* Surgically altered detrusor muscle (i.e. Augmentation cystoplasty)\n* Current or prior bladder malignancy\n* Prior pelvic irradiation\n* Post void residual (PVR) \\>\u002F= 150 mL within 6 months prior to enrollment\n* Active urinary tract infection\n* Primary stress urinary incontinence or mixed urinary incontinence with stress predominance\n* \\>\u002F= Stage III pelvic organ or vaginal vault prolapse and\u002For current pessary use",true,{"count":85,"type":20},193,[58],"Sacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a percutaneous nerve evaluation (PNE) or a stage implantation. Patients who experience a \\> 50% improvement in UUI symptoms progress to permanent implantation. PNE offers significant advantages compared to a staged implantation including a single anesthetic and operating room trip. Historically, full implantation rates are only 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation after PNE may be attributed to lead migration. Newer data suggest up to 90% of PNE trials lead to full implantation. The investigators hypothesize that shortening PNE trial time to 3 days from 7 days will not result in a lower proportion of PNE trials leading to SNM implantation and may offer less time for lead migration. The investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to SNM implantation.",[27,63,62],[90,91,92,30,93,94],"urinary urgency","urinary incontinence","urinary frequency","sacral neuromodulation","percutaneous nerve evaluation","2026-02-04",{"date":97,"type":37},"2026-02-09",{"date":99,"type":37},"2023-12-10",{"date":101,"type":20},"2026-12-31",{"name":103,"class":44},"University of Chicago",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":124,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100622722","phase-4-a-randomized-placebo-controlled-trial-of-nitrous-oxide-during-in-office-bladder-botox-injections-100622722","NCT07387315","A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","A Randomized, Placebo Controlled Trial of Nitrous Oxide\u002FOxygen Plus Standard Care Versus Standard Care Alone During In-office Intradetrusor onabotulinumtoxinA (Botox) Injections","Inclusion Criteria:\n\n* Adult women ≥18 years old scheduled for in-office intradetrusor botulinum toxin injection and able to consent.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected vitamin B12 or folate deficiency or high-risk state (e.g., pernicious anemia, malabsorption, post-bariatric or strict vegan without supplementation)\n* currently pregnant\n* severe\u002Funstable pulmonary disease or baseline hypoxemia requiring supplemental home oxygen\n* eye or ear surgery in the last six weeks\n* trapped-air conditions (e.g., untreated pneumothorax, bowel obstruction)\n* severe active otitis\u002Fsinus disease\n* inability to follow directions\n* history of adverse reaction to nitrous oxide",{"count":112,"type":20},96,[23],"The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure?\n\nResearchers will compare a 50:50 nitrous oxide\u002Foxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain.\n\nParticipants will:\n\n* Receive their bladder Botox injection in the office setting\n* Either use nitrous oxide\u002Foxygen plus standard care during the procedure, or sham mask plus standard care\n* Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure",[62,116,27,117,118,119,120,121,122,123],"Neurogenic Bladder","Pain","Urinary Incontinence","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Bladder Neurogenesis","Urinary Incontinence, Urge","Pelvic Floor Disorders",[62,118,27,125,126,127,128,129,130,131,132,133,134,135],"Intradetrusor Injection","OnabotulinumtoxinA","Botox","Bladder Botox","Botulinum Toxins, Type A","Pain Management","Analgesia","Nitrous Oxide","Office-based Procedures","Urogynecology","Pelvic Floor Disorder","NOT_YET_RECRUITING","2026-01-28",{"date":95,"type":37},{"date":140,"type":20},"2026-02",{"date":142,"type":20},"2026-12",{"name":144,"class":44},"TriHealth Inc.",2,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":169},"100491922","a-real-world-study-of-ecoin-for-urgency-urinary-incontinence-post-approval-evaluation-recipe-100491922","NCT05685433","A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)","RECIPE","Inclusion Criteria:\n\n* Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population\n* Individual with diagnosis of overactive bladder with urgency urinary incontinence.\n* Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.\n* Individual gives written informed consent.\n* Individual is mentally competent and able to understand all study requirements.\n* Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.\n* Individual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to baseline or longer if the physician judges that the therapeutic effect is still present.\n* Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).\n* Individual is determined to be a suitable surgical candidate by physician.\n* Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.\n\nExclusion Criteria:\n\n* Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.\n* Individual has clinically significant bladder outlet obstruction. (Suspected bladder outlet obstruction will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has predominantly stress urinary incontinence (greater than 1\u002F3 of leaks on baseline diary are stress).\n* Individual has an active urinary tract infection at time of enrollment.\n* Individual has known polyuria.\n* Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome.\n* Individual has abnormal post void residual (i.e. greater than 200 cc initially and on repeat testing after double voiding)\n* Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by uroflow study with those having a maximum flow rate \\\u003C 15mL\u002Fs requiring additional evaluation.)\n* Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.\n* Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.\n* Individual has had diagnosis of bladder, urethral, or prostate cancer.\n* Individual has had a prior anti-stress incontinence sling surgery within the last year.\n* Individual is pregnant or intends to become pregnant during the study.\n* Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.\n* Individual has uncontrolled diabetes mellitus (Hemoglobin A1C\\>7) or diabetes with significant peripheral complications. (Uncontrolled diabetes will be ruled out by blood test excluding those with Hemoglobin A1C\\>7).\n* Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator (ICD).\n* Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment, or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual has been treated with percutaneous tibial nerve stimulation (PTNS) within the previous 4 weeks prior to enrollment or more time if the principal investigator judges that the therapeutic effect is present.\n* Individual is currently using transcutaneous electrical nerve stimulation (TENS) in the pelvic region, back, or legs.\n* Individual is aware that he or she will need an MRI scan other than a head\u002Fneck\u002Fshoulder MRI during the study period.\n* Individual has a clotting or bleeding disorder or is using anticoagulant therapies and in the opinion of the investigator is not a good candidate for the study (antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator).\n* Individual is neutropenic or immune-compromised.\n* Individual has had previous surgery and\u002For significant scarring at the implant location.\n* Individual has ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders.\n* Individual has a clinically significant peripheral neuropathy in the lower extremities.\n* Individual has neurogenic bladder dysfunction.\n* Individual has pitting edema at implant location (≥ 2+ is excluded).\n* Individual has inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.\n* Individual has varicose veins and is symptomatic.\n* Individual has open wounds, trauma, or prior surgery in the lower extremities.\n* Individual has arterial disease in the lower extremities.\n* Individual has vasculitis in the lower extremities.\n* Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBC's \u002FHPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)\n* In the opinion of the investigator, Individual is not a good candidate for participation in the study.",{"count":154,"type":20},200,[58],"A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).",[62,27,158,159],"Incontinence, Urinary","Urinary Urge Incontinence","2026-01-26",{"date":137,"type":37},{"date":163,"type":37},"2023-01-26",{"date":165,"type":20},"2031-12",{"name":167,"class":168},"Valencia Technologies Corporation","INDUSTRY",22,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":177,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100506437","ucon-treatment-of-overactive-bladder-oab-in-males-100506437","NCT05874375","UCon Treatment of Overactive Bladder (OAB) in Males","Safety and Performance of UCon for Management of Non-Neurogenic OAB in Males - An Early Feasibility Study","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age.\n2. Subject is male.\n3. Subject is diagnosed with OAB\n4. Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation.\n\nExclusion Criteria:\n\n1. Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation).\n2. Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)).\n3. Subject has an active infection in the genital area incl. skin infections and urinary tract infection.\n4. Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months.\n5. Subject has used antimuscarinics or β3 agonists within 14 days weeks\\*.\n6. Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).\n7. Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment.\n8. Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.\n9. Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region.\n10. Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.\n11. Subject does not speak and understand Dutch.\n\n    * If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.","MALE",{"count":179,"type":20},20,[58],"UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.",[118,27,183,184,122,185],"Nocturia","Urinary Frequency More Than Once at Night","Incontinence, Nighttime Urinary",[118,187,188,189,183],"Urge incontinence","Neurostimulation","Dorsal Genital Nerve","2025-09-30",{"date":192,"type":37},"2025-10-01",{"date":194,"type":37},"2023-10-12",{"date":196,"type":20},"2026-06-12",{"name":198,"class":168},"InnoCon Medical",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":210,"phases":4,"briefSummary":211,"conditions":212,"keywords":213,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100594868","assessing-the-genitourinary-microbiome-of-women-with-overactive-bladder-undergoing-onabotulinum-toxin-type-a-intradetrusor-injections-100594868","NCT07025044","Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","Characterizing the Postmenopausal Genitourinary Microbiome in Women Undergoing Onabotulinum Toxin Type A for Overactive Bladder - A Feasibility Trial","MICROAB_Pilot","Inclusion Criteria:\n\n* Natal female \\> 55 years old\n* English-speaking\n* Scheduled to undergo onabotulinum toxin type A for treatment of OAB\n* No menses for \\>1 year if uterus in situ\n* Planning one dose nitrofurantoin for antibiotic prophylaxis at time of onabotulinum toxin type A injection per clinic protocol\n\nExclusion Criteria:\n\n* Diagnosis of painful bladder syndrome\n* Current symptomatic or clinically-suspected UTI within 30 days prior to onabotulinum toxin type A injection procedure\\*\n* Systemic antibiotic exposure within 30 days\\^\n* Prophylactic antibiotic treatment for recurrent UTI within the last 12 months\n* Current systemic immunosuppressive therapy (i.e. prednisone or immunomodulators) immunotherapy, chemotherapy or radiation treatment\n* Prior pelvic radiation\n* Indwelling catheter or intermittent catheterization","55 Years",{"count":209,"type":20},40,"OBSERVATIONAL","Single-site prospective observational pilot feasibility study of women with overactive bladder\u002Furge urinary incontinence undergoing onabotulinum toxin type A intradetrusor injections in order to achieve the following objectives:\n\n* Establish a record of successful collaboration with Dr. Ravel, an expert researcher in the female microbiome based at the University of Maryland\n* Demonstrate the investigators' ability to recruit subjects from the diverse population of postmenopausal women undergoing BTX for OAB within MedStar Health Urogynecology clinics\n* Collect, process and analyze urine specimens collected prior to and 4-weeks after BTX injection, and to compare the GU microbiome of self-collected versus clinic-collected samples\n* Assess response to BTX treatment and explore rates of and risk factors for urinary tract infection and incomplete voiding requiring catheterization within the first 4-weeks after BTX",[26,27],[214],"onabotulinum toxin type A","2025-09-08",{"date":217,"type":37},"2025-09-12",{"date":219,"type":37},"2025-09-03",{"date":221,"type":20},"2026-06-01",{"name":223,"class":44},"Alexis Dieter",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":45},"100569541","phase-4-optimal-intravesical-lidocaine-volume-for-pain-relief-during-office-intra-detrusor-onabotulinum-toxin-a-injections-100569541","NCT06695585","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections","Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections: a Prospective Randomized Superiority Trial","Inclusion Criteria:\n\n* Adult female, \\>18 years, English-speaking (surveys utilized are not validated in all languages)\n* Able to provide informed consent\n* Indications: Refractory urge urinary incontinence, Refractory urinary urgency and frequency, Neurogenic bladder (without sensory deficit)\n\nExclusion Criteria:\n\n* Untreated urinary tract infection at the time of procedure\n* Contra-indication to Botox\n* Contraindication to intravesical lidocaine\n* Inability to provide informed consent\n* Pregnancy, breast-feeding, intending to become pregnant within 6 months of treatment",{"count":232,"type":20},36,[23],"The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.",[62,236,237,238,27,116],"Overactive Bladder Syndrome","Urinary Urgency","Urinary Frequency",[128,240,241],"Intravesical lidocaine","office Botox","2024-11-15",{"date":244,"type":37},"2024-11-19",{"date":246,"type":20},"2024-12-01",{"date":248,"type":20},"2025-12-01",{"name":250,"class":44},"University of Louisville"]